Director, EMEA Regulatory Lead Multiple Myeloma
Janssen Pharmaceutical Companies of Johnson & Johnson
Els Caenen, PharmD, is an EMEA regulatory leader at Janssen with over 20 years' experience in clinical development of which 15+ years’ working in regulatory affairs, initially in the field of Infectious diseases and vaccines and most recently in haematology with a focus on multiple myeloma, an orphan-designated condition. Over the past years, under Els' leadership, several PRIME designated products were granted marketing authorisation, including Carvykti and Tecvayli for the treatment of multiple myeloma.
Disclosure information not submitted.
EMA's PRIME Scheme in Review: Findings, Lessons Learnt and Future Directions
Friday, May 12, 2023
10:45 – 11:45 CEST